KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in RRMM
MYELOMA CLINICAL TRIALS - Active




- Jun 10, 2021
NCT04798586: Phase 1: MAGNETISMM-2: Study of Elranatamab (PF-06863135) in Japanese Patients Myeloma


- Jun 9, 2021
NCT04892446: Phase 2: Study of Magrolimab Combinations in Participants With Relapsed/Refractory MM


- Dec 17, 2020
NCT04555551:Phase 1 - MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for Multiple Myeloma


- Dec 10, 2020
NCT04246047: Phase 3: Belantamab Mafodotin, Bortezomib and Dex RRMM Myeloma (DREAMM 7)


- Dec 3, 2020
NCT04552743: Phase 2: MGTA-145 + Plerixafor in the Mobilization of Hematopoietic Stem Cells for ASCT


- Dec 2, 2020
NCT04649359: Phase 2 - MagnetisMM-3: Elranatamab (PF-06863135) Monotherapy in relapsed Myeloma


- Dec 28, 2019
NCT04181827: Phase 3 -Cilta-cel vs Pom/Bort/Dex or Dara/Pom/Dex in relpsd. len ref MM CARTITUDE 4


- Dec 27, 2019
NCT04196491: Phase 1 - Evaluate the Safety of bb2121 in High Risk, New Myeloma (NDMM) (KarMMa-4)


- Dec 21, 2019
NCT03984097: Phase 1: A Study to Evaluate Subcutaneous TAK-079 Added to Standard Regimens NDMM


- Dec 19, 2019
NCT04045795: Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)


- Dec 13, 2019
NCT04000282: Phase 1: First-in-human Single Agent Study of SAR442085 in Relapsed or Refractory MM


- Dec 13, 2019
NCT04083534: Phase 1/2: First In Human (FIH) Study of REGN5459 in Adult Patients With Relapsed RRMM


- Dec 11, 2019
NCT04035226 - Study of Real-life Current Standards of Care in Patients With RRMM with 3 prior lines


- Dec 10, 2019
NCT03940833: Phase 1/2: Adoptive BCMA CAR-NK Cells - RRMM


- Dec 8, 2019
NCT038282: Phase 1 - Dose Esc Study Belantamab mafodotin (GSK2857916) in Japanese With Refr MM


- Dec 7, 2019
NCT03859427: Phase 3: Once-weekly vs Twice-wkly Carfilzomib + Lenalidomide + Dex RRMM - A.R.R.O.W.2


- Dec 6, 2019
NCT03975907: Phase 1/2 - Clinical Trial to Evaluate CT053 in Patients With RRMM (LUMMICAR STUDY 1)


- Dec 3, 2019
NCT03836053: Phase 1b - AMG 420 in Subjects With Relapsed and/or Refractory Multiple Myeloma AMG420


- Dec 2, 2019
NCT04182581: Phase 1: A Study of BCMA/CD19 Dual-Target CAR-T Cell Immunotherapy for Relapsed Myeloma


- Dec 1, 2019
NCT03798678: Phase 1 - CB-839 HCl + Carfilzomib and Dex - Refractory MM


- Dec 1, 2019
NCT03848845: Phase 1/2: GSK2857916 in Combination With Pembrolizumab in RRMM Myeloma- DREAMM 4


- Dec 30, 2018
NCT03652064 : Phase 3 - Bortezomib, Lenalidomide, Dex and +/- Daratumumab - NDMM - MMY3019 CEPHEUS


- Dec 27, 2018
NCT03549442: Phase 1 - CART-BCMA +/- huCART19 as Consolidation High Risk MM


- Dec 26, 2018
NCT03548207: Phase 1b -2 - JNJ-68284528, CAR-T Therapy against BCMA in relapsed MM (CARTITUDE-1)


- Dec 20, 2018
NCT03430011: Phase 1/2 - Autologous BCMA-specific CAR-T cells JCARH125 in RRMM (EVOLVE)


- Dec 15, 2018
NCT03710603: Phase 3 - Daratumumab, VELCADE, Len, Dex VS VELCADE, Len, Dex in NDMM (Perseus) EMN17


- Dec 14, 2018
NCT03412565: Phase 2 - Subcutaneous Daratumumab in Combination With Standard MM Regimens - PLEIADES


- Dec 13, 2018
NCT03606577: Phase 2-IFM 2018 - 04 - Quadruplet Induction & Consolidation + Tandem ASCT Hi Risk NDMM


- Dec 12, 2018
NCT03716856: Phase 1 - CAR-BCMA T in Patients With Refractory or Relapsed Multiple - Chinese study


- Dec 7, 2018
NCT01554852: Phase 3- Thalidomide, Lenalidomide, Carfilzomib, Bortezomib, Vorinostat-NDMM Myeloma XI


- Dec 6, 2018
NCT03617731: Phase 3 - Effect of Isatuximab to RVd Induction and Len Maintenance in NDMM (GMMG HD7)


- Dec 6, 2018
NCT03544281: Phase 2: GSK2857916 /Len/Dex Vs GSK2857916/Bortezomib/Dex - RRMM Myeloma - DREAMM 6


- Dec 5, 2018
NCT03650491: Phase 1: A Study of FOR46 in Patients With Relapsed or Refractory Multiple Myeloma


- Dec 4, 2018
NCT03525678: Phase 2 - Two Doses of GSK2857916 in Myeloma who have failed Anti-CD38 Ab. DREAMM 2


- Dec 31, 2017
NCT03290950: Phase 2 - A Study of Daratumumab in Patients With NDMM wKRd-D - Manhattan Trial


- De